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Abstract
Over the last decade a significant number of studies have highlighted the central role of host antimicrobial (or defence)
peptides in modulating the response of innate immune cells to pathogen-associated ligands. In humans, the most widely
studied antimicrobial peptide is LL-37, a 37-residue peptide containing an amphipathic helix that is released via proteolytic
cleavage of the precursor protein CAP18. Owing to its ability to protect against lethal endotoxaemia and clinically-relevant
bacterial infections, LL-37 and its derivatives are seen as attractive candidates for anti-sepsis therapies. We have identified a
novel family of molecules secreted by parasitic helminths (helminth defence molecules; HDMs) that exhibit similar
biochemical and functional characteristics to human defence peptides, particularly CAP18. The HDM secreted by Fasciola
hepatica (FhHDM-1) adopts a predominantly a-helical structure in solution. Processing of FhHDM-1 by F. hepatica cathepsin
L1 releases a 34-residue C-terminal fragment containing a conserved amphipathic helix. This is analogous to the proteolytic
processing of CAP18 to release LL-37, which modulates innate cell activation by classical toll-like receptor (TLR) ligands such
as lipopolysaccharide (LPS). We show that full-length recombinant FhHDM-1 and a peptide analogue of the amphipathic C-
terminus bind directly to LPS in a concentration-dependent manner, reducing its interaction with both LPS-binding protein
(LBP) and the surface of macrophages. Furthermore, FhHDM-1 and the amphipathic C-terminal peptide protect mice against
LPS-induced inflammation by significantly reducing the release of inflammatory mediators from macrophages. We propose
that HDMs, by mimicking the function of host defence peptides, represent a novel family of innate cell modulators with
therapeutic potential in anti-sepsis treatments and prevention of inflammation.
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Introduction
The detection of microbial invasion by cells of the innate
immune response (macrophages and dendritic cells; DCs) occurs
via receptor recognition of specific microbial molecular patterns
(pathogen-associated molecular patterns; PAMPS), such as the
Gram-negative lipopolysaccharide (LPS) endotoxin. Interaction
between cell receptors and bacterial PAMPS drives the early
immune response and leads to maturation of anti-microbial
responses manifested in the production of potent pro-inflamma-
tory cytokines such as IL-6, IL-12 and TNF [1]. While the
production of these cytokines, together with up-regulation of co-
stimulatory molecules on DCs, macrophages, granulocytes and
mast cells, is a critical step in the development of appropriate
protective adaptive immune responses, an excessive inflammatory
response can lead to sepsis, septic shock and death [2,3].
Human defence peptides are potent signalling molecules released
by cells of the innate immune system in response to cellular
stimulation by microbes and pro-inflammatory mediators [4].
Multiple peptides are simultaneously secreted at the site of infection
and/or inflammation and work cooperatively to perform broad-
spectrum antimicrobial activities [5,6]. While it is well recognized
that defence peptides participate as direct antimicrobial effectors of
innate immunity by disrupting bacterial membranes [7], more
recent studies suggest that they are also important in the regulation
of innate immune responses and are critical in protecting against the
detrimental effects of an excessive innate inflammatory response.
Thus, defence peptides have been shown to suppress LPS-mediated
responses [3,8], promote phagocytosis while inhibiting oxidant
responses of neutrophils or monocytes [9,10], and inhibit pro-
inflammatory cytokine secretion by macrophages in the presence of
bacteria or other non-specific inflammatory stimuli [6,10].
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It has been demonstrated experimentally that intestinal injury
and systemic endotoxemia are two factors leading to morbidity in
helminth infection of mice [11,12]. Disruption to the barrier
function of the intestinal epithelium and consequently the
translocation of luminal antigens (bacteria and their toxins) into
the circulation is common to many helminth parasites. Thus,
infection with enteric nematodes is characterised by enhanced
leakiness of the intestinal epithelium, mediated by activated mast-
cells [13], which aids the expulsion of the parasite from the host but
can lead to the movement of bacterial LPS into the portal
circulation [14]. Even in non-enteric helminths, such as the
schistosomes that reside in the mesenteric veins, damage caused
by worm eggs traversing the intestinal epithelium can result in the
systemic translocation of bacteria [11]; for example, E. coli are
frequently detected in the mesenteric lymph nodes of Schistosoma
mansoni-infected patients [15]. Biliary obstruction due to the growth
of Fasciola hepatica worms in the bile ducts increases intraductal
pressure leading to the disruption of hepatocellular tight junctions
and subsequent translocation of E. coli and enterococcus [16,17].
Despite such bacterial colonisation, potent host responses such as
septicaemia are not common events during helminth infections.
While the mechanism of resistance to septicaemia during helminth
infection is poorly understood, it is known that innate immune cells
rather than those of the adaptive immune system play an essential
protective role. For example, mice deficient in the IL-4a receptor
specifically on macrophages and neutrophils, but not T-cells,
experienced high mortality (100%) associated with increased sepsis
following infection with S. mansoni [11,12].
Here we describe a novel family of proteins that is secreted by
medically-important trematode pathogens. As these proteins
display similar functional and biochemical characteristics to the
human defence peptides, defensins and cathelicidins, we have
termed them helminth defence molecules (HDMs). We have
characterised the HDM secreted by F. hepatica (FhHDM-1), and
show that proteolytic processing of this molecule by a co-secreted
cathepsin L1 releases a 34-residue C-terminal fragment containing
an amphipathic helix. This amphipathic peptide is conserved
amongst the HDMs of the major trematode pathogens of humans
and exhibits similar structural features to LL-37, an anti-microbial
peptide proteolytically released from the human cathelicidin
precursor, CAP18. Recombinant FhHDM-1 and a synthetic
peptide corresponding to the amphipathic C-terminal fragment
bind directly to LPS in a concentration-dependent manner, block
its interaction with LPS-binding protein (LPB), and prevent it
binding to the surface of macrophages. Furthermore, both
FhHDM-1 and the amphipathic C-terminal peptide protect mice
against LPS-induced inflammation by significantly reducing the
release of inflammatory mediators from macrophages. We propose
that HDMs represent a novel family of helminth modulators of
host innate immunity that are responsible for preventing the
induction of sepsis during infection.
Results
A novel family of helminth defence molecules (HDMs)
Fractionation by gel filtration chromatography of proteins
secreted by adult F. hepatica yielded two major peaks, termed PI
(.200 kDa) and PII (20–60 kDa) (Figure 1A). Because of different
separation techniques employed in the present study the elution
and protein profiles of PI and PII appear slightly different from
those presented in our earlier studies [18]. We have shown
previously that PI contains the anti-oxidant peroxiredoxin (Prx;
[18,19]). However, SDS-PAGE analysis revealed that this fraction
contains another major component with a molecular mass around
8 kDa (Figure 1B). Whilst it is not fully understood why this 8 kDa
protein is the most abundant species in the .200 kDa PI fraction,
we suspect that it forms aggregates with other secretory proteins,
including peroxiredoxin [18]. These aggregates are dispersed by
RP-HPLC using acetonitrile in the mobile phase allowing the
8kDa protein to be isolated to homogeneity (Figure 1B, lane E). N-
terminal sequencing of this band generated a single clean sequence
(SEESREKLRE) that matched a putative peptide encoded by
several F. hepatica ESTs (e.g. HAN3008-1e06.p1k) following
tBLASTn analysis. This N-terminal sequence is identical to the
first ten amino acids of a sequence reported by McGonigle et al.
[20] within a high molecular mass fraction of F. hepatica secretory
proteins, although the identity of the protein remained elusive
until the present study.
Analysis of the conceptually translated Fasciola ESTs using SignalP
[21] predicted a signal peptide of residues 1-20. However, N-terminal
sequencing of the native protein showed that residues 1–22 were
removed upon secretion (Figure 1D). RT-PCR was performed to
verify the coding region of the cDNA; the resulting 222 bp cDNA
included a 210 bp open reading frame encoding a 70 amino acid
mature protein (Figure 1D; GenBank accession no. HQ456365).The
mature protein was predicted from primary sequence to have a
molecular mass of 8 kDa, which is close to that observed by SDS-
PAGE (Figure 1B) and Western blot analysis of the native F. hepatica
secretions using an anti-FhHDM-1 antibody (Figure 1C). Analysis of
the FhHDM-1 primary sequence using InterProScan [22] did not
detect any known functional domains or motifs. However, our
analysis of the predicted secondary structure suggested structural
homology with host defence peptides and in particular human
CAP18/LL-37 (Figure 2) and, therefore, we termed the novel protein
F. hepatica helminth defence molecule-1 (FhHDM-1).
Analysis of cDNA and available genomic databases using
tBLASTn [23] identified putative homologues of FhHDM-1 in
related trematodes that are major pathogens of humans, including
the liver flukes Clonorchis sinensis and Opisthorchis viverrini, the lung
fluke Paragonimus westermani, and the blood flukes S. mansoni and S.
japonicum (Figure 3A and B). The FhHDM-1 protein aligns with a
7 kDa protein (55% sequence identity) derived from a C. sinsensis
cDNA [24] and with the C-terminal region (,30% sequence
identity) of the S. mansoni secreted protein Sm16 [25]. The
evolutionary relationships of FhHDM-1 and the related trematode
Author Summary
The study of pharmacologically active peptides is central
to the understanding of disease and the development of
novel therapies. Of particular interest is the array of short
cationic peptides, collectively known as antimicrobial (or
host defence) peptides. In humans, the most widely
studied host defence peptide is LL-37. This a-helical
peptide is expressed by neutrophils, macrophages and
mucosal epithelial cells and modulates the response of
innate immune cells to pathogen-associated ligands (such
as bacterial lipopolysaccharide). We have identified a novel
family of molecules secreted by medically-important
helminth pathogens (termed helminth defence molecules;
HDMs) that exhibit striking structural, biochemical and
functional similarities to host defence peptides, including
LL-37. HDMs bind LPS preventing the activation of
macrophages and the release of pro-inflammatory medi-
ators that can cause sepsis. We propose that HDMs
modulate the immune response via molecular mimicry of
host defence peptides, thus creating a unique opportunity
for novel anti-infective therapy.
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cDNA/EST sequences (17 in all) deposited in the public databases
and at http://www.sanger.ac.uk/Projects/Helminths/was investi-
gated at the molecular level by constructing a bootstrapped
neighbour-joining tree (Figure 3A). A phylogenetic analysis
revealed that these sequences separated into three clades which
segregated the Sm16-like molecules from the HDMs which
themselves were split into two clades corresponding to schistosome
HDMs and those of Fasciola and the Asian flukes. Despite this
segregation, all HDM clade members share a number of
similarities including (a) a predicted N-terminal signal peptide (b)
a predicted a-helical secondary structure, and (c) a largely
hydrophobic C-terminal portion of approximately 35 residues
that is the most conserved region of the molecule both within and
between clades (Figure 3B).
The expression of the FhHDM-1 gene in NEJs, 21-day
immature liver stage flukes and adult F. hepatica was determined
by RT-PCR using the expression of the housekeeping gene b-actin
as a loading control. FhHDM-1 was constitutively expressed in all
three life-cycle stages (Figure 3C, top). The protein is also clearly
secreted during all stages of host infection as an antibody response
against FhHDM-1 was detected in the serum of experimentally-
infected sheep corresponding to the migratory stages (4–8 weeks
post-infection) and against mature worms residing in the bile ducts
(.12 weeks post-infection) (Figure 3C, bottom).
Native and recombinant FhHDM-1 possess significant
a-helical structure
Secondary structure predictions using PSIPRED [26] indicate
that FhHDM-1 has a high propensity to form a-helices
(Figure 1D). In order to demonstrate this experimentally, CD
spectroscopy was used to estimate the secondary structure of both
native (purified as described above) and recombinant FhHDM-1.
Full-length FhHDM-1, lacking the predicted N-terminal signal
peptide, was expressed in E. coli as a 9.2 kDa recombinant protein
fused to a C-terminal His6-tag for purification. The recombinant
FhHDM-1 protein was isolated to homogeneity from E. coli cell
lysates by a combination of Ni-chelate affinity chromatography
and RP-HPLC (Figure 4A).
CD spectroscopy was performed in solution in the presence or
absence of 30% (v/v) TFE at pH 4.5 and pH 7.3. The resulting
spectra display double minima at 208 nm and 222 nm, indicative
of a-helical structure. In order to confirm this assertion, the CD
spectra were fitted by nonlinear least squares regression using the
CDPro software package employing the CDSSTR, CONTINLL
and SELCON3 algorithms [27]. The best fit for each sample,
resulting from the CONTINLL algorithm against the SP29
database [28], predicted both native and recombinant FhHDM-1
to have predominantly a-helical secondary structure in the
presence and absence of 30% (v/v) TFE at both pH 4.5 and
pH 7.3 (Table S1). Given their similarity, a CD spectrum
representative for all samples analysed (recombinant FhHDM-1
at pH 7.3) is shown in Figure 4B.
FhHDM-1 oligomerisation is enhanced at low pH
Despite having a molecular mass of 8 kDa, native FhHDM-1 is
found within a high molecular mass fraction (PI; .200 kDa)
following gel filtration of adult Fasciola secretory proteins (Figure 1A
and B). Therefore, analytical ultracentrifugation was performed to
Figure 1. Identification and characterisation of native FhHDM-1. (A) Secretory proteins collected from adult F. hepatica following in vitro
culture were separated by gel filtration and the resulting high molecular mass (.200 kDa) peak (peak I; PI) was separated further using reverse phase
HLPC (RP-HPLC). Fractions collected following gel filtration and RP-HPLC were run on reducing 4–12% Bis-Tris gels (B) and showed that a prominent
, 6 kDa protein present in total adult secretory proteins (S) was enriched in PI and purified to homogeneity (.95%) following RP-HPLC (E). (C)
Western blot of adult fluke secretions probed with an anti-FhHDM-1 antibody. P, pre-immune sera; T, test bleed. (D) N-terminal sequencing and LC-
MS/MS analysis of the native , 6 kDa protein generated peptide sequence information that allowed cloning of the cDNA, termed FhHDM-1. The
primary amino acid sequence of FhHDM-1 derived from conceptual translation of the cDNA is shown. The predicted N-terminal signal peptide is
shown in italics and the actual N-terminal of the native protein is shown by an arrow. The SEESREKLRE sequence generated by N-terminal sequencing
is boxed in grey and a peptide (m/z 642.93; ITEVITILLNR) matched by LC-MS/MS following tryptic digest of the native protein is underlined. Secondary
structure predictions using using PSIPRED [26], shown below the primary sequence, suggest the molecule is predominantly a-helical.
doi:10.1371/journal.ppat.1002042.g001
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investigate the quaternary structure of recombinant FhHDM-1
(Mr = 9277.6) in aqueous solution. Sedimentation velocity studies
were employed at an initial protein concentration of 0.1 mg/ml at
pH 4.5 and pH 7.3. The absorbance versus radial position profiles
of FhHDM-1 at pH 4.5 (Figure S1A, bottom panel) and pH 7.3
(Figure S1B, bottom panel) show a predominantly single
sedimenting boundary suggesting the samples are primarily
homogeneous. However, there is a small proportion of a slower
sedimenting boundary in the sample buffered at pH 4.5 (Figure
S1A, bottom panel). To confirm the presence of multiple species,
the absorbance versus radial position data at different time points
were fitted to a continuous sedimentation coefficient distribution
model [29–31] (Figure 5A). This yielded excellent fits for all
samples as represented by the random distribution of residuals
(Figure S1A and B, top) and the excellent statistical parameters
resulting (i.e. rmsd values ,0.0063 and Runs test Z values ,8.8).
From the ordinate maximum of the distributions shown in
Figure 5A, the standardized sedimentation coefficient (s20,w) of
FhHDM-1 at pH 7.3 is 2.5 S, whilst at pH 4.5, the s20,w values of
the two peaks observed in the c(s) distribution (Figure 5A, Table
S2) are 3.1 S (major species) and 2.0 S (minor species). The
equivalent continuous mass [c(M)]-distribution analyses of the
same data (Figure 5B) suggest that the 2.5 S species at pH 7.3 is a
trimer, whereas the 2.0 S species and predominant 3.1 S species at
pH 4.5 correspond to dimers and pentamers, respectively
(Figure 5B, solid line; Table S2). However, the broad c(s) and
c(M) distributions at pH 4.5 is more likely to indicate that the
sample exists as a mixture of dimers, trimers, tetramers, pentamers
and potentially hexamers (Figures 5A and 5B, solid lines). In
contrast, recombinant FhHDM-1 potentially exists as dimers,
trimers and/or tetramers in solution at pH 7.3 (Figures 5A and
5B, dashed lines). Although the exact oligomeric identities of the
species are beyond the resolution of the sedimentation velocity
experiment, the data summarized in Figure 5 nevertheless
demonstrates that FhHDM-1 has a greater propensity to form
higher order oligomers at acidic pH compared to neutral pH.
FhHDM-1 exhibits structural similarity to human defence
molecules
The unusual helical nature of FhHDM-1 provided the impetus
to conduct a bioinformatic search for small molecules with a
similar structure. Helical wheel analysis (http://kael.net/helical.
htm) revealed the presence of an amphipathic helix within this C-
terminal region for all the trematode HDMs; for FhHDM-1 this is
comprised of residues 69-89 (Figure 2A and B). This is supported
by the CD spectroscopy studies (Figure 4B). This amphipathic
helix is found in many small peptide antimicrobials and defensins
[32]. Further probing discovered a striking structural similarity
between the HDMs and the human defence molecule CAP18.
CAP18 is larger than FhHDM-1 (170 as opposed to 90 residues)
but regions of conservation exist between the two molecules
throughout their lengths. Most importantly, the C-terminal
Figure 2. FhHDM-1 is structurally homologous with LL-37. (A) Primary sequence alignment of FhHDM-1 with the human LL-37 precursor,
hCAP18. The LL-37 processing site is arrowed. (B) Helical wheel analysis shows that the conserved C-terminal hydrophobic regions boxed in (A) form
amphipathic helices in both molecules.
doi:10.1371/journal.ppat.1002042.g002
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regions of both molecules exhibit high conservation, with a
signature motif EKI[X9]R[X2]D[X]L. It is known that CAP18 is
secreted and undergoes cleavage in this C-terminal region by
endogenous proteases to release the bioactive 37-residue peptide
LL-37 containing an amphipathic helix. As shown in Figure 2, this
helical structure is also found in FhHDM-1 and conserved in other
trematode HDMs.
F. hepatica cathepsin L1 cysteine protease releases
bioactive FhHDM-1 peptides
To examine whether FhHDM-1 is processed to release
peptides similar to LL-37, F. hepatica secretory proteins collected
from in vitro culture supernatants were concentrated using 3 kDa
molecular weight cut-off filters. The flow-though from these filters
contained a single major band of ,3.5 kDa as shown by reducing
4–12% Bis-Tris gel electrophoresis (Figure 6A). Although
attempts to obtain N-terminal sequence information from this
band were unsuccessful, a high-scoring FhHDM-1 peptide
(ITEVITILLNR; m/z 642.93) was identified by LC-MS/MS
analysis of trypsin digests of the 3.5 kDa band (Figure 6D). These
data indicate that, like human CAP18, native FhHDM-1 is
processed into smaller peptide fragments by parasite proteases.
The most likely candidate for this processing event are the
cathepsin L proteases, which we have previously shown are major
components of the secretory products of F. hepatica and other
trematodes [33,34].
To investigate whether F. hepatica cathepsin L1 (FhCL1) can
process FhHDM-1, recombinant FhHDM-1 was incubated with
recombinant FhCL1 [35] at pH 4.5 or pH 7.3. Analysis of the
reactions by SDS-PAGE showed that, at pH 4.5, the 9.2 kDa
band corresponding to full-length recombinant FhHDM-1 had
decreased in intensity concurrent with the appearance of a
number of smaller protein fragments, notably, a prominent band
with a molecular mass of ,8.5 kDa (Figure 6B). The putative
Figure 3. Phylogenetic relationships of the HDMs. (A) A bootstrapped (1000 trials) neighbour-joining phylogenetic tree showing the
evolutionary relationship of HDM cDNA sequences from medically-important trematode pathogens. Numbers represent bootstrap values (given as
percentages) for a particular node, and values greater than 65% are shown. The tree is rooted to human CAP18 (accession number NM_004345).
Three major clades are shown corresponding to the Sm16-like molecules, the schistosome HDMs and HDMs from Fasciola and the Asian flukes. (B)
Primary sequence alignment of selected members of the HDM clades. Conserved residues that contribute to the hydrophobic face of the
amphipathic helix are shaded in grey. (C) Top panel. RT-PCR analysis of FhHDM-1 expression in F. hepatica newly excysted juveniles (NEJ), 21-day
immature flukes (21d) and adult worms (Adult). Amplification of constitutively expressed F. hepatica b-actin was performed as a positive control.
Samples were separated by agarose gel electrophoresis and stained with ethidium bromide. Bottom panel. Immunogenicity of FhHDM-1 in F.
hepatica-infected sheep. Pre-infection sera (Pre) and samples taken 4, 8, 12 and 16 weeks post-infection were analysed by ELISA and Western blot
using an anti-FhHDM-1 antibody. Specific antibody responses were detected at week 4 with immunoblot staining stronger at weeks 8 and 12 after
infection.
doi:10.1371/journal.ppat.1002042.g003
Molecular Mimicry of Host Antimicrobial Peptides
PLoS Pathogens | www.plospathogens.org 5 May 2011 | Volume 7 | Issue 5 | e1002042
degradation products did not react with an anti-His antibody
suggesting that the C-terminal region of the recombinant
FhHDM-1 had been removed. Furthermore, an anti-FhHDM-1
antibody detected a number of the smaller protein fragments,
suggesting that the full-length protein had been cleaved by FhCL1
at pH 4.5. In contrast, FhHDM-1 was not processed by FhCL1
under identical incubation conditions at pH 7.3 (Figure 6B).
The FhHDM-1 fragments produced by cathepsin L were
analysed by MALDI TOF MS. Several minor peaks were found,
but the major masses detected were matched to full-length
recombinant FhHDM-1 6 the C-terminal His-tag (m/z 9272.88
and 8450.53, respectively) and a 37-amino acid C-terminal
fragment (m/z 4232.44) created by cleavage after Arg56 (native
peptide numbering; Figure 6C). Whilst the N-terminal fragment
Figure 4. Expression and CD spectroscopy of recombinant FhHDM-1. (A) The full-length FhHDM-1 cDNA, minus the N-terminal signal
peptide, was expressed in E. coli and the His-tagged recombinant was purified from cell lysates using Ni-NTA agarose (Qiagen). P, pre-column; FT,
flow-through; W, wash, E1, imidazole eluate. Co-eluting proteins were removed by RP-HLPC resulting in recombinant FhHDM-1 of very high purity
(E2). (B) CD spectra of recombinant 0.1 mg/mL21 FhHDM-1 at pH 7.3. The wavelength scan was performed between 190 and 250 nm. The final
spectrum (closed circles in the absence of 30% (v/v) TFE and open circles in the presence of 30% (v/v) TFE) is the average result from three scans
measured at 20uC. The CONTINLL algorithm from the CDPro software package [27] produced the best fit (solid lines) against the SP29 protein
database [28] with r.m.s.d. values for all samples #0.325. FhHDM-1 adopts a near identical solution structure in both native and recombinant form at
both pH 4.5 and pH 7.3 (data not shown). The resulting secondary structure proportions are reported in Table S1.
doi:10.1371/journal.ppat.1002042.g004
Figure 5. Sedimentation velocity analysis of recombinant FhHDM-1. (A) Continuous size-distribution analysis, c(s), plotted as a function of
sedimentation coefficient for recombinant FhHDM-1 at pH 4.5 (solid line) and pH 7.3 (dashed line). Continuous size-distribution analysis was
performed using the program SEDFIT [29–31] employing 100 sedimentation coefficients ranging from 0.1 S to 6.0 S and at a confidence level (F-ratio)
= 0.95. (B) Continuous mass, c(M), distribution plotted as a function of molecular mass (kDa) for recombinant FhHDM-1 at pH 4.5 (solid line) and
pH 7.3 (dashed line). Continuous mass-distribution analysis was performed using SEDFIT with 100 masses ranging from 1.0 kDa to 80 kDa and at a
confidence level (F-ratio) = 0.95.
doi:10.1371/journal.ppat.1002042.g005
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created by cleavage after Arg56 also matched this mass (Figure 6C),
the presence of a C-terminal FhHDM-1 peptide in the ,3.5 kDa
band found in the Vivaspin filter flow-through supports its
identification as the C-terminal fragment. Based on this putative
cleavage site, a 34-residue synthetic peptide (FhHDM-1 p2)
corresponding to this C-terminal region of the molecule was
designed for subsequent analysis (Figure 6D). It is noteworthy that
the cathepsin L cleavage site that produces the FhHDM-1 p2
peptide is, based on primary sequence alignments, only one amino
acid N-terminal to the proteolytic cleavage of human CAP18 that
releases the bio-active LL-37 peptide (see Figure 2).
Recombinant FhHDM-1 and FhHDM-1 p2 bind LPS
A major function of human LL-37 is the neutralisation of
bacterial LPS. Given the structural similarity between FhHDM-1
and CAP18/LL-37, the ability of FhHDM-1 and derived
peptides to likewise bind LPS from E. coli 0111:B4 was
determined (Figure 7B and C). Both full-length native and
recombinant FhHDM-1 bound to LPS via specific interaction
with its secondary structure. The specificity of this interaction was
demonstrated by an un-related recombinant protein (expressed/
purified in the same manner as FhHDM-1) that displayed less
than 25% of the LPS binding shown by FhHDM-1 (data not
shown). Furthermore, recombinant FhHDM-1 and the C-
terminal peptide FhHDM-1 p2 (containing the complete
amphipathic helix) bound to LPS in a concentration-dependent
manner. However, peptide FhHDM-1 p1, in which the
amphipathic helix is truncated (Figure 7A), did not bind to
LPS. The specific interaction between FhHDM-1 and LPS was
supported by experiments in which FhHDM-1 and FhHDM-1 p2
were mixed with increasing concentrations of LPS during the
ELISA. As shown in Figure 7D, both molecules bound to free
LPS in solution and were therefore unable to bind LPS
immobilised on the ELISA plate.
Figure 6. FhCL1 processes FhHDM-1 at low pH. (A) Total secretory proteins from adult F. hepatica were concentrated from culture supernatants
using a 3 kDa cut-off filter. 10 mg of the flow-through (FT) was analysed on a 4–12% Bi-Tris gel and stained with Flamingo fluorescent protein stain.
The FT comprised a single prominent band (, 3.5 kDa) that was identified by LC-MS/MS as an FhHDM-1 fragment (high-scoring peptide ITEVITILLNR;
m/z 642.93, underlined in D). N-terminal sequencing of this band was unsuccessful. (B) To investigate whether F. hepatica cathepsin L1 (FhCL1) can
process FhHDM-1, 50 mg recombinant FhHDM-1 was incubated with 1 mg recombinant FhCL1 [35] in either 0.1 M sodium acetate (pH 4.5) or 0.1 M
sodium phosphate (pH 7.3) each containing 1 mM EDTA and 1 mM DTT. Reactions were performed 6 FhCL1 for 3 h at 37uC and stopped by the
addition of E-64 (10 mM). Samples were analysed on 4–12% Bis-Tris gels and blots were probed with anti-His or anti-FhHDM-1 antibodies. (C) The
pH 4.5 reaction in the presence of FhCL1 shown in (B) was analysed by MALDI-TOF MS. The major masses detected correspond to the full length
recombinant FhHDM-1 6 the C-terminal His-tag (m/z 9272.88 and 8450.53 respectively) and two fragments (both m/z 4232.44) created by a single
cleavage after Arg56 (native peptide numbering). (D) The putative FhHDM-1 cleavage sites are arrowed. Based on this, the synthetic peptide FhHDM-1
p2 was designed (shown as a cartoon above the primary sequence of recombinant FhHDM-1). Whilst trypsinising recombinant FhHDM-1
considerably reduced its interaction with LPS, boiling had no effect.
doi:10.1371/journal.ppat.1002042.g006
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Recombinant FhHDM-1 and FhHDM-1 p2 block the
interaction of LPS with LPS-binding protein (LPB)
The ability of FhHDM-1 and derived peptides to block the
interaction of LPS with LPB was assessed by ELISA using an anti-
LBP primary antibody. Since it is a well-characterised a-helical
defence peptide, human LL-37 was used for comparison. As
shown in Figure 7E, F. hepatica ES (p = 0.039), full-length FhHDM-
1 (p = 0.0002) and FhHDM-1 p2 (p = 0.001) significantly reduced
the interaction between LPS and LBP as effectively as LL-37
(p = 0.002). However, FhHDM-1 p1 did not block the interaction
of LPS with LPB. Thus, the ability of FhHDM-1 to block the
interaction of LPS with LPB is mediated by its conserved C-
terminal domain.
Recombinant FhHDM-1 and FhHDM-1 p2 inhibit binding
of FITC-LPS to RAW264.7 macrophages
The effect of FhHDM-1 and derived peptides on the binding of
FITC-LPS to CD14+ cells was determined by flow cytometry of
the murine macrophage cell line RAW264.7. The assay was
performed at 4uC to inhibit endocytosis, thus ensuring that only
cell-surface interactions were observed. FITC-LPS bound to
RAW264.7 cells strongly in the absence of parasite molecules or
LL-37 and this binding was inhibited (70% inhibition) by LL-37
(Figure 7F). FhHDM-1 p2 (58% inhibition) and full-length
FhHDM-1 (29% inhibition) also considerably reduced FITC-
LPS binding when used at 5 mg/ml (Figure 7F). In contrast,
incubation with FhHDM-1 p1 increased FITC-LPS binding to the
cell surface by 29%.
Recombinant FhHDM-1 and FhHDM-1 p2 prevent
LPS-induced inflammatory response in mice
By inhibiting the interaction between bacterial LPS and
macrophages, FhHDM-1 and derived peptides are predicted to
prevent the activation of an inflammatory immune response. To
investigate this, BALB/c mice were injected intra-peritoneally with
1 mg of LPS alone or LPS combined with 1 mg of FhHDM-1,
FhHDM-1 p3 or LL-37. Serum was collected 2 h later, and levels
of the pro-inflammatory mediators TNF and IL-1b were measured
by ELISA. As expected, a single dose of LPS increased the levels of
both TNF and IL-1b in circulation (Figure 8A and 8B). However,
Figure 7. LPS neutralisation by FhHDM-1. (A) Alignment of full-length FhHDM-1 with peptide 1 (FhHDM-1 p1) and peptide 2 (FhHDM-1 p2). The
conserved C-terminal amphipathic helix is shaded in grey. (B) The ability of native and recombinant FhHDM-1 to bind LPS was investigated by
incubating the proteins (2 mg/well) in an LPS-coated (100 ng/well) microtitre plate. Bound proteins were detected by ELISA using rabbit anti-FhHDM-
1 as a primary antibody. BSA was used as a baseline control. Whilst trypsinising the recombinant FhHDM-1 significantly reduced the LPS interaction,
boiling had no effect. (C) The ability of recombinant FhHDM-1 (D), FhHDM-1 p1 (N) or FhHDM-1 p2 (&) to bind to LPS was investigated by incubating
a range of concentrations of proteins (0.02–2 mg/well) in this assay. (D) FhHDM-1 or derived peptides (0.1 mg) were incubated in the presence of LPS
(0.05-5 mg/well) and bound peptides measured as described above. Binding of peptides to the LPS-immobilised plates was expressed as a percentage
of that measured for 2 mg (for panel C) or 0.1 mg (for panel D) of FhHDM-1. Data are the means 6 SD from three separate experiments. (E) FhHDM-1
and FhHDM-1 p2 but not FhHDM-1 p1 reduced the interaction between LPS and LBP as effectively as LL-37. LPS-coated microtitre plates were
incubated with 5 mg/well of F. hepatica ES, LL-37, FhHDM-1 or derived peptides for 1 h prior to the addition of 10% human sera in PBS. Interaction of
LBP with LPS was measured by ELISA using an anti-LBP primary antibody and expressed as a percentage of that detected for 10% sera in the absence
of added peptides. Data are the mean 6 SD of three separate experiments. Statistical significance was calculated using the student t-test and
represent a comparison to the binding of 10% sera to immobilised LPS. (F) Binding of FITC-conjugated LPS to RAW264.7 cells was inhibited by LL-37,
FhHDM-1 and peptides. RAW264.7 cells (56105cells/ml) were incubated with 100 ng/ml of FITC-conjugated LPS in the presence of FhHDM-1, FhHDM-
1 p1, FhHDM-1 p2 and LL-37 (5 mg/ml) in RPMI 1640 containing 10% FBS for 20 min at 4uC. The binding of FITC-LPS was analysed by flow cytometry.
Values represent percentage inhibition of FITC-LPS binding compared to cells in the absence of peptides. Data are the mean fluorescence 6 SD of
three independent experiments.
doi:10.1371/journal.ppat.1002042.g007
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when mixed with FhHDM-1, FhHDM-1 p2 or LL-37, LPS failed
to induce an equivalent immune response, with levels of serum
TNF and IL-1b significantly reduced (Figure 8A and 8B). Because
macrophages are the main source of pro-inflammatory mediators
in this murine model of inflammation, we examined whether the
decrease in circulating cytokines could be attributed to a reduction
in the activation of macrophages. Peritoneal macrophages were
isolated from treated mice (LPS 6 FhHDM-1, peptides or LL-37
as described above), and the quantity of TNF and IL-1b secreted
into culture media over 16 h was measured by ELISA. Correlating
with the sera data, macrophages isolated from mice injected with
LPS alone showed elevated levels of both TNF and IL-1b
compared to PBS-treated mice (Figure 8C and 8D) whereas
production of TNF was decreased in the presence of FhHDM-1 or
FhHDM-1 p2. Interestingly, LL-37 did not have a significant
effect on LPS-induced secretion of TNF from macrophages in this
assay (Figure 8C). This contrasts with previous studies [36–38] but
may be due to a number of experimental differences such as the
doses of LPS and LL-37 given, the serotype of LPS, and the time
of cellular isolation. In addition, the full-length recombinant
FhHDM-1 or LL-37 (but not FhHDM-1 p2) also reduced the
release of IL-1b from peritoneal macrophages in response to LPS
(Figure 8D).
Discussion
Using proteomics and database mining we have identified a
novel family of secretory proteins from trematode pathogens
(termed helminth defence molecules; HDMs) that exhibit similar
biochemical and functional characteristics to human defence
peptides.
Host defence (also termed antimicrobial) peptides represent an
evolutionarily conserved component of innate immunity [39].
Their potent antimicrobial activity has led to suggestions that
they are involved not only in suppressing inflammation in the
presence of pathogenic challenge, but also in maintaining
homeostasis by limiting inflammatory responses that could
otherwise be triggered by the presence of commensals [40].
They are widely distributed in nature, from insects and plants to
highly evolved animal species with more complex immune
systems [41]. Although the peptides identified to date show
considerable diversity in their lengths, structures and activities,
they are all generally amphipathic, possessing both cationic
(positively charged) and hydrophobic faces [42,43]. These
features bestow the peptides with antimicrobial activity by
facilitating interactions with negatively charged microbial cell
membrane components (e.g., phospholipids), thereby increasing
membrane permeability and resulting in microbial death [44].
Owing to the lack of primary sequence similarity [32,45],
peptides are broadly classified based on secondary structure as
cathelicidins (linear a-helical peptides), defensins (b-strand
peptides connected by disulfide bonds), and bactenecins (loop
peptides) [46]. Using this classification, the 8 kDa protein
(FhHDM-1) secreted by F. hepatica could be termed a cathelicidin
as CD spectroscopy studies indicate that both native and
recombinant FhHDM-1 have a high propensity to adopt a-
Figure 8. FhHDM-1 protects mice from LPS-induced inflammation. (A) BALB/c mice were injected intra-peritoneally with 1 mg of LPS alone or
combined with 1 mg of FhHDM-1, FhHDM-1 p2 or LL-37. Two hours later, sera was collected and serum levels of TNF and (B) IL-1bmeasured by ELISA.
(C) Peritoneal macrophages were isolated, cultured unstimulated in media overnight and then levels of TNF and (D) IL-1b in the culture measured by
ELISA. Data are the mean 6 SD of six mice in each group. Statistical significance represents a comparison to the levels of cytokines secreted by mice
given LPS only.
doi:10.1371/journal.ppat.1002042.g008
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helical structure in the presence or absence of helix-stabilising
agents in both neutral and acidic pH conditions.
In humans, the most widely studied cathelicidin LL-37 is
expressed by neutrophils, macrophages and mucosal epithelial
cells in response to stimulation by microbes and proinflammatory
mediators [45,47]. LL-37 is secreted as an inactive precursor
protein known as CAP18 that undergoes cleavage by endogenous
proteases to release the bioactive 37-residue peptide LL-37
[48,49]. Similarly, the secreted FhHDM-1 can be processed by
the major cysteine protease (cathepsin L1; FhCL1) from F. hepatica
to release a C-terminal peptide fragment. Despite having activity
over a broad pH range [50] FhCL1 could only process FhHDM-1
at pH 4.5, which is similar to the pH of the Fasciola gut lumen.
Similarly, FhCL1 can only digest host haemoglobin at pH#4.5 as
relaxation of the haemoglobin structure at acidic pH makes it
susceptible to proteolysis [50]. It is unlikely that local relaxation of
the FhHDM-1 structure accounts for its proteolysis at low pH
since it adopts almost identical solution structures at both pH 4.5
and pH 7.3. Moreover, full-length FhHDM-1 and its C-terminal
fragment were both found in native fluke secretions, suggesting
that not all FhHDM-1 molecules are cleaved in the parasite gut.
The greater propensity of FhHDM-1 to oligomerise at low pH
(predominantly existing as pentamers) may render individual
FhHDM-1 molecules inaccessible to the active site of FhCL1 thus
offering some degree of protection against proteolysis. Whilst
FhCL1 is the most abundant protease secreted by adult flukes, is it
possible that other cathepsin cysteine proteases (e.g. FhCL2,
FhCL5 and cathepsin B) could also process FhHDM-1 in vivo. It is
also possible that FhHDM-1 may be cleaved by host proteases at
neutral pH. This would be an ideal mechanism for regulating the
activity of the secreted parasite molecule until it reaches its site of
action on/within host cells.
Residues 13–34 of LL-37 form an amphipathic helix that
anchors the peptide to phospholipid membranes via interaction
with its hydrophobic face [48,51] and is important for its
antimicrobial ability [3]. In addition to these potent bactericidal
activities, LL-37 can also bind to LPS and neutralize its biological
activities. Among the host defence peptides, only the cathelicidin
CAP18-derived peptides (human and rabbit) and CAP11 display
an ability to bind to LPS [36,52,53]. In contrast, defensins exhibit
little, if any, LPS-binding activity [36,54]. It has been suggested
that it is the amphipathic helical structure of the cathelicidin
peptides that is critical for interacting with LPS [55,56]. Indeed,
LL-37-derived peptides covering residues 13–34 are as effective as
full-length LL-37 with respect to LPS binding [57]. The 34-residue
C-terminal peptide of FhHDM-1 released by cleavage with
FhCL1 contains a 21-residue amphipathic helix which confers a
striking structural parallel with the bioactive LL-37 peptide. In
addition, a peptide (FhHDM-1 p2) derived from the C-terminal of
FhHDM-1 containing the complete amphipathic helix binds E. coli
LPS in a concentration-dependent manner. In stark contrast, a
second peptide, FhHDM-1 p1, in which the amphipathic helix is
truncated, did not bind LPS. Although recognising FhHDM-1,
sera isolated from sheep at 4 weeks and 8 weeks post-infection with
F. hepatica did not block binding of FhHDM-1 to LPS (data not
shown). This is likely as a result of the sera binding the non-
amphipathic region of the molecule, and the amphipathic helix
remaining free to interact with LPS. Thus, the amphipathic helix
of FhHDM-1, like LL-37, is a key functional determinant
necessary for its biological properties.
Bacterial LPS is recognized as a key molecule in the
pathogenesis of endotoxin shock associated with gram-negative
bacterial infections [2,58,59]. By binding to LPS, LL-37
successfully neutralises its biological activities [52]. Similarly,
FhHDM-1 targets key stages in LPS-mediated cell signalling. The
first event in the recognition of microbial infection is the transfer of
LPS to cellular CD14 by serum LPS-binding protein (LBP). This
LPS-CD14 complex then initiates downstream signalling via
interaction with cellular TLRs [60], which results in the secretion
of inflammatory mediators. By binding directly to LPS, FhHDM-1
and FhHDM-1 p2 blocked the interaction of LPS with LBP, thus
effectively reducing the number of LPS molecules that are targeted
to the TLR signalling complex on the macrophage cell surface.
This in turn prevents LPS-induced activation of macrophages.
Therefore, FhHDM-1, and its conserved C-terminal region, just
like human LL-37, impair LPS signalling and protect against
harmful immune responses by reducing the release of inflamma-
tory mediators from macrophages. In contrast, FhHDM-1 p1
increased FITC-LPS binding to the surface of RAW264.7
macrophages by 29%. Enhanced LPS binding to immune cells
has previously been observed for other proteins such as
bactericidal/permeability increasing protein [61] and surfactant
protein A [62] but the molecular mechanism of this phenomenon
for any of these immunomodulatory peptides/proteins has yet to
be determined. One possible explanation is that some molecules
induce mobilization (and surface expression) of LPS-binding
proteins from intracellular vesicles [63].
By preventing the activation of innate immune responses by
LPS, the helminth parasite enhances the survival of the host and
thus its own longevity. As mentioned in the introduction, the
translocation of intestinal bacteria into circulation is common
during many helminth infections [11,13–15]. Despite this
movement of enteric microbes, fatal septicaemia during infection
with trematodes including S. mansoni is not a common occurrence
[64]. Indeed, there are, as yet, no reports of such in intestinal
nematodes. In addition, in areas endemic for helminth parasites,
co-infection with gram-negative bacteria, most commonly Salmo-
nella sp., is common [65]. This results in a protracted clinical
course of bacterial disease and yet patients show atypical
symptoms of typhoid fever displaying only intermittent fever and
chills [66,67]. The reason why the helminth-infected host does not
respond to such increases in potentially harmful microbes is not
fully understood. One explanation given is that the conversion of
macrophages to an alternatively activated phenotype during
helminth infection renders them unresponsive to subsequent
Th1 activation [68]. However, other reports suggest that
macrophages are not terminally differentiated but display some
degree of plasticity [69]. Moreover, despite long-term exposure to
Th2 cytokines in vivo during a helminth infection, macrophages
are nevertheless responsive to LPS, developing a classically
activated phenotype characterised by the expression of iNOS
[70]. Other studies demonstrate that IL-4 and IL-13 can prime
macrophages for secondary microbial challenge leading to
enhanced secretion of proinflammatory cytokines [71]. Therefore,
during a helminth infection it is likely that a wide spectrum of
macrophage phenotypes exists, displaying varying degrees of
responsiveness to bacterial ligands. We propose that the active
secretion of FhHDM-1 by the parasite throughout its time in the
mammalian host ensures that potentially lethal LPS, either from
intestinal flora or from microbial co-infections, is neutralised and
that LPS-mediated activation of macrophages is controlled.
Consequently, excessive inflammatory responses are avoided and
the survival of the host, and therefore the parasite, are prolonged.
It is noteworthy that the HDMs show homology with the C-
terminal region of the Sm16 protein from S. mansoni and its S.
japonicum homologues [72,73]. Like FhHDM-1, Sm16 forms
oligomers, modulates LPS-mediated TLR signalling in human
monocytes (albeit via a different mechanism to the HDMs) and its
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biological activity is mediated by its C-terminal region [72]. Thus,
it is possible that the HDMs and the Sm16-like molecules evolved
from a common ancestral protein and represent sub-clades of a
larger family of helminth innate cell modulators. Our discovery of
a family of HDMs that is conserved amongst medically-important
trematode pathogens that modulate the immune response via
molecular mimicry of host defence peptides provides a common
mechanism for the anti-inflammatory properties of helminth
infection.
While many cationic amphiphilic compounds are being
developed as therapeutics based on their potent antimicrobial
activity [74,75], only derivatives of LL-37 have been proposed as
attractive candidates for anti-sepsis therapies [32]. Our discovery
of a novel family of HDMs derived from worm parasites provides a
new pool of bio-active peptides that may have unique pharma-
cological properties with prospects for the development of novel
anti-inflammatory therapeutics.
Materials and Methods
Preparation of adult F. hepatica secretory proteins
Mature Fasciola hepatica, were recovered from the liver tissue and
bile ducts of Merino sheep 16 weeks after an experimental
infection with 200 infective stage larvae (metacercariae) and
washed in pre-warmed (37uC) PBS pH 7.3. Flukes were then
transferred to pre-warmed (37uC) RPMI 1640 medium (Invitro-
gen) containing 2 mM L-glutamine, 30 mM HEPES, 0.1% (w/v)
glucose and 2.5 mg/ml gentamycin and incubated for 8 h at 37uC.
The culture medium containing F. hepatica secretory proteins was
pooled and concentrated using Vivapsin columns (VivaScience)
with a 3 kDa molecular weight cut-off to a final concentration of
1 mg/ml and stored in aliquots at 220uC. The flow-through from
the Vivaspin columns was concentrated to approximately 1 mg/
ml using a Concentrator 5301 (Eppendorf) and stored in aliquots
at 220uC until use.
Biochemical purification of native FhHDM-1 from
F. hepatica secretions
Concentrated F. hepatica secretory proteins (1 mg) were
separated by size exclusion chromatography (gel filtration) using
a Superdex 75 HiLoad 16/60 column (GE Healthcare) attached to
a BioLogic LP system (BioRad). Samples were resolved with PBS,
pH 7.3, at a flow rate of 1 ml/min. The eluant was monitored at
220 nm and 0.5 ml fractions were collected over time. The major
peak with a calculated molecular mass .200 kDa (termed PI;
[18]) that was observed following gel filtration was further resolved
by reverse phase high performance liquid chromatography (RP-
HPLC) using an Agilent 1200 HPLC (Agilent Technologies, Palo
Alto, CA) fitted with a Phenomenex Jupiter 5m C4 300 A˚ column
(15062.0 mm). The column flow rate was 100 mL/min and
samples were eluted using a gradient of buffer A (0.1% TFA and
2% acetonitrile) and buffer B (0.1% TFA and 98% acetonitrile).
The eluted proteins were detected at 220 nm and 0.5 ml fractions
were collected by an automated fraction collector based on peak
detection.
Synthetic FhHDM-1 peptides
FhHDM-1 peptide 1 (FhHDM-1 p1) is 30 residues in length,
corresponding to residues 51–80 (KARDRAMAYLAKDNLGE-
KITEVITILLNRL), and was designed as a truncation of the C-
terminal amphipathic helix. FhHDM-1 p2 is 34 residues in length
and corresponds to residues 56–89 (AMAYLAKDNLGEKITE-
VITILLNRLTDRLEKYAG). It was designed to match the C-
terminal fragment of FhHDM-1 containing the complete
amphipathic helix that is released following cleavage by FhCL1.
LL-37 and peptides derived from FhHDM-1 were synthesised by
GL Biochem (Shanghai, China).
N-terminal sequencing and LC-MS/MS
Protein samples from RP-HLPC fractions were analysed using
NuPageH NovexH 4–12% Bis-Tris gels (Invitrogen). NuPageH LDS
sample buffer plus Sample Reducing Agent (Invitrogen) were
added to the samples and heated at 95uC for 5 min prior to
electrophoresis. Proteins were then transferred to polyvinylidene
fluoride (PVDF) immobilon-P membranes (Millipore) at 120 mA
for 45 min. The membranes were washed with distilled water and
stained with 0.025% Coomassie Brilliant Blue R-250 in 40%
methanol, 10% acetic acid. Selected protein bands were subjected
to 5 cycles of N-terminal (Edman) sequencing using an Applied
Biosystems 494 Procise Protein Sequencing System at the
Australian Proteome Analysis Facility (Sydney, Australia).
Liquid chromatography tandem mass spectrometry (LC-MS/
MS) analysis was performed as described previously [34,76].
Briefly, individual gel bands were cut into smaller pieces
(approximately 1 mm2) and reduced and alkylated with 5 mM
tributylphosphine and 20 mM acrylamide (Sigma) in 100 mM
NH4HCO3 for 90 min. The excised sections were digested in-gel
with trypsin (Sigma Proteomics grade) and the peptides solubilised
with 2% formic acid (Sigma) prior to analysis by LC-MS/MS
using a Tempo nanoLC system (Applied Biosystems) with a C18
column (Vydac) coupled to a QSTAR Elite QqTOF mass
spectrometer running in IDA mode (Applied Biosystems). Peak
list files generated by the Protein Pilot v1.0 software (Applied
Biosystems) using default parameters were exported to a local
PEAKS (Bioinformatics Solutions Inc.) search engine and
employed as queries to search a custom-made database composed
of all F. hepatica ESTs (14,031 reads) currently available from the
Wellcome Trust Sanger Centre (ftp://ftp.sanger.ac.uk/pub/
pathogens/Fasciola/hepatica/ESTs/). The enzyme specificity
was set to trypsin, propionamide (acrylamide) modification of
cysteines was used as a fixed parameter and oxidation of
methionines was set as a variable protein modification. The mass
tolerance was set at 100 ppm for precursor ions and 0.2 Da for
fragment ions and only one missed cleavage was allowed. Only
high-scoring (.60%) peptides were considered to be significant
[76].
F. hepatica RNA extraction and RT-PCR
Newly excysted juvenile (NEJ) flukes were recovered from
dormant metacercariae (Baldwin Aquatics, OR, USA) using a
method developed in our laboratory as described by Robinson et al.
[76]. Immature F. hepatica (21 day-old) were recovered from the
livers of female BALB/c mice (experimentally infected with 20
metacercariae; [76]) while adult parasites were recovered from the
bile ducts of Merino sheep as described above. Total RNA was
prepared from F. hepatica NEJs, immature flukes and adult parasites
using Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. Contaminating genomic DNA was removed by
treatment with DNAse I (Promega). Reverse transcription was
performed with 1 mg total RNA using an oligo(dT)15 primer and
200 U M-MLV (H-) reverse transcriptase (Promega) at 50uC for 1 h
according to the manufacturer’s instructions. Aliquots of the
resulting cDNA from each life-cycle stage (200 ng) were subjected
to PCR amplification under the following conditions: 94uC for
1 min, 58uC for 30 s and 72uC for 1 min with a final extension at
72uC for 5 min. A total of 30 cycles were performed. The following
gene-specific primers were designed using an adult F. hepatica EST
(identifier HAN3008-1e06.p1k) and used for PCR: FhHDM-1_F1
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59-CATATGAGACCTAGCGAGGAAAGCCG-39 and FhHDM-
1_R1 59-CTCGAGATTTCCCGCGTATTTCTCCAAG-39. RT-
PCR amplification of constitutively expressed F. hepatica b-actin was
performed as a positive control. PCR products were separated by
1% agarose gel electrophoresis and stained with ethidium bromide.
Expression and purification of recombinant FhHDM-1 in
E. coli
The FhHDM-1 protein coding sequence downstream of the
predicted N-terminal signal peptide was amplified using the
Expand High Fidelity PCR system (Roche) with the primers
FhHDM-1_F1 and FhHDM-1_R1 and cloned into the pCR2.1
TOPO vector (Invitrogen). Following DNA sequencing at the
Australian Genome Research Facility (Brisbane, Australia), the
insert was sub-cloned into NdeI/XhoI restriction sites of the
pET21b expression vector (Novagen) and Escherichia coli strain
BL21 transformed with the resulting constructs. Bacterial cultures
(1 L) were grown in LB media supplemented with ampicillin
(100 mg/ml) at 37uC until OD600 0.4–0.6 and expression of the
recombinant FhHDM-1 was induced by the addition of 1 mM
IPTG for 4 h at 37uC. Cell pellets were collected by centrifugation
at 4000 x g for 20 min at 4uC and then resuspended in lysis buffer
(300 mM KCl; 50 mM KH2PO4; 5 mM imidazole). Cells were
lysed by sonication at maximum power for six cycles of 10 s on/
50 s off. Cleared lysate was obtained by centrifugation at 10000 x
g for 30 min at 4uC. Soluble recombinant His-tagged FhHDM-1
protein was purified and desalted using the Profinia Protein
Purification System (BioRad) according to manufacturer’s instruc-
tions. Briefly, the cleared lysate was loaded onto a 1 mL IMAC
column and washed with 6 column volumes of lysis buffer
(300 mM KCl; 50 mM KH2PO4; 5 mM imidazole) followed by a
second wash containing 10 mM imidazole. Protein was eluted in
the same buffer containing 250 mM imidazole and loaded directly
onto a 10 mL desalting column. The final desalted recombinant
FhHDM-1 protein was eluted in PBS (pH 7.3) and stored in
aliquots at 220uC until use. The purified full-length recombinant
FhHDM-1 was also used to raise polyclonal antibodies in rabbits
(Auspep, Australia).
Processing of FhHDM-1 by FhCL1
Processing of FhHDM-1 was carried out by mixing 50 mg of the
purified recombinant with 1 mg recombinant F. hepatica cathepsin
L1 (FhCL1; [35]). The mixtures were incubated in either 0.1 M
sodium acetate (pH 4.5) or 0.1 M sodium phosphate (pH 7.3)
each containing 1 mM EDTA and 1 mM DTT for 3 h at 37 uC.
Reactions were performed 6 FhCL1 and stopped by the addition
of E-64 (10 mM). Samples were analysed on 4–12% Bis-Tris gels
and stained with Flamingo fluorescent protein stain (Invitrogen) or
transferred to nitrocellulose membranes for immuno-detection.
Blots were blocked with 5% nonfat dry milk in PBS Tween (0.05%
v/v) and incubated with either a 1:10,000 dilution of rabbit
antiserum raised against recombinant FhHDM-1 or a 1:1000
dilution of a mouse anti-His6 antibody (Abcam) and subsequently
with alkaline phosphatase-conjugated goat anti-rabbit/mouse IgG
(Sigma) for 1 h. Blots were visualised by the addition of 3,3-
diaminobenzidine peroxidase substrate (Sigma).
To identify the peptide fragments resulting from FhCL1
processing of FhHDM-1, samples of the reaction performed at
pH 4.5 were analysed by Matrix Assisted Laser Desorption
Ionisation (MALDI) mass spectrometry at the Australian Pro-
teome Analysis Facility. Briefly, samples were mixed 1:1 with
a-cyanohydrocinnamic acid (1 mg/mL in 90% acetonitrile
containing 0.1% TFA) and spotted (1 mL) onto a MALDI plate
that contained a dried matrix spot from 0.5 mL matrix. An
additional spot of matrix (1 mL) was added and dried. A protein
calibration spot was spotted next to the sample in the same
manner. MALDI MS was performed using an AB Sciex 4800+
instrument using a Nd:YAG laser (355 nm) to irradiate the
sample. Spectra were acquired in positive mode in the mass range
2,000–20,000 Da with a mass accuracy of 650 Da. The mass
spectrometer was calibrated using Bruker calibrant proteins.
Enzyme-linked immunosorbent assay and immunoblot
analysis
Serum samples were obtained from six male Merino sheep
experimentally infected with F. hepatica. Serum samples were taken
8 weeks prior to infection with 200 metacercariae and on weeks 4,
8, 12 and 16 post-infection and used for ELISA and immuno-
blotting. One hundred microliters of recombinant FhHDM-1
(5 mg/ml) was dispensed into the wells of microtiter plates that
were then incubated overnight at 4uC. Excess protein binding sites
were blocked at 37uC for 1 h by adding 200 ml of 1% bovine
serum albumin diluted in PBS containing 0.1% Tween 20 (PBST)
to each well. After the wells were washed three times with PSBT,
sheep sera (diluted 1:1000) was added and the plates were
incubated for 2 h at 37uC. Following another wash, 100 ml of
alkaline phosphatase-conjugated anti-sheep IgG (diluted 1:10,000)
was added to each well and the plates were incubated for an
additional 1 h at 37uC. After another washing step, bound
antibodies were detected by the addition of 200 ml of p-nitrophenol
phosphate (1 mg/ml) in 0.2 M Tris buffer, pH 8.0. After the
colour had developed for 30 min, the plates were read on a Power
Wave HT (BioTek) at 405 nm. All assays were tested in triplicate.
Sera from individual animals that showed sero-positivity for
FhHDM-1 by the above ELISA method were selected for
immunoblot analysis. Briefly, 10 mg of recombinant FhHDM-1
or adult F. hepatica secretory proteins were run on reducing
NuPageH NovexH 4–12% Bis-Tris gels (Invitrogen) and transferred
to PVDF immobilon-P membranes (Millipore) at 120 mA for
45 min. Following transfer, the membranes were incubated in
blocking solution (TSBT: 20 mM Tris–HCl, 150 mM NaCl, 1%
Tween-20, pH 7.6) containing 5% skimmed milk for 3 h at room
temperature. Sheep antisera were diluted 1:1000 in TBST
containing 1% skimmed milk and applied to the membranes
overnight at 4uC. After washing in TSBT (4610 min), an alkaline
phosphatase-conjugated anti-sheep-IgG secondary antibody was
applied to the membranes for 30 min at room temperature before
detection using p-nitrophenol phosphate (1 mg/ml) in 0.2 M Tris
buffer, pH 8.0.
Circular dichroism spectroscopy
Circular dichroism (CD) spectra were recorded using an AVIV
410-SF CD spectrometer. Wavelength scans were performed
between 190 and 250 nm in either 10 mM Tris, 50 mM NaF
buffer (pH 7.3) or 10 mM sodium citrate, 50 mM NaF buffer
(pH 4.5) in both the presence and absence of 30% (v/v) TFE with
a sample concentration of 0.1 mg mL21. Spectra were recorded in
a 1 mm quartz cuvette at 20 uC. Data below 195 nm for the native
FhHDM-1 sample at both pH 7.3 and pH 4.5 were removed from
analyses due to low signal-to-noise. Data were analyzed using the
CDPro software package [27].
Analytical ultracentrifugation
Sedimentation velocity experiments were conducted in a
Beckman model XL-I analytical ultracentrifuge at a temperature
of 20uC. Samples were analysed at a concentration of 0.1 mg/ml
in either 10 mM Tris, 50 mM NaF buffer (pH 7.3) or 10 mM
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sodium citrate, 50 mM NaF buffer (pH 4.5). Samples were loaded
into a conventional double sector quartz cell and mounted in a
Beckman 4-hole An-60 Ti rotor. 380 ml of sample and 400 ml of
reference solution were centrifuged at a rotor speed of
40,000 rpm, and the data were collected at a single wavelength
(230 nm) in continuous mode, using a step-size of 0.003 cm
without averaging. Solvent density (1.0014 g/ml at pH 4.5 at
20uC and 1.0000 g/ml at pH 7.3) and viscosity (1.0077 cp at
pH 4.5 and 1.0174 at pH 7.3) were determined using a Density
Meter and Automated Microviscometer (Anton Paar) and
estimates of the partial specific volume (0.7327 ml/g for
recombinant FhHDM-1) were computed using the FhHDM-1
amino acid composition employing the program SEDNTERP
[77]. Sedimentation velocity data at multiple time points were
fitted to a single discrete species and a continuous size-distribution
model [29-31] using the program SEDFIT, which is available at
www.analyticalultracentrifugation.com.
Bioinformatics and phylogenetic analysis
FhHDM-1 orthologs in other trematodes related to F. hepatica
were identified following tBLASTn analysis of the NCBI
nucleotide and EST databases (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) using the FhHDM-1 primary sequence as search query.
Specific searches were also performed against the various F.
hepatica (http://worm1.liv.ac.uk/blast/blast.html), S. mansoni
(http://www.sanger.ac.uk/DataSearch/blast.shtml) and S. japoni-
cum (http://function.chgc.sh.cn/sj-proteome/blastn.htm) genome
and transcriptome databases. The trematode HDM primary
sequences were aligned using CLUSTAL W [78]. Secondary
structure prediction was performed using PSIPRED [26] and
amphipathic helix prediction was performed using helical wheel
analysis (http://www.kael.net/helical.htm). Phylogenetic trees
were created using 17 trematode cDNA sequences that encoded
full-length HDM proteins but excluding the signal peptide. The
DNA sequences were initially aligned using CLUSTAL W [68]
and the trees were created using the boot-strapped (1000 trials)
neighbour-joining method of MEGA version 4.0 [79], using the
Kimura 2 parameter model with uniform rates for all sites. The
GenBank accession numbers/EST identifiers of the sequences
used for alignment and phylogenetic analyses are as follows.
Schistosome HDMs: FN314266, AM047184, FN314265,
FN314266, FN314267, FN357430; Fasciola/Asian fluke HDMs:
HQ456365, AF281362, AT009171, AT007125, ES416124;
Sm16-like molecules: AF109180, EF127841, AY812960,
AY814368, AY915075 and FN327058. The phylogenetic tree
was rooted with human CAP18 (accession number NM_004345).
Measurement of the LPS-binding activities of FhHDM-1
and derived peptides
Microtiter plates (96 well; Nunc) were coated with E. coli LPS
(100 ng/well; serotype 111:B4; Sigma) in PBS for 3 h at 37uC,
following which the plates were rinsed thoroughly under running
water and air-dried overnight. After blocking excess binding sites
with 1% BSA/PBS, native and recombinant FhHDM-1 or derived
peptides (0.02-2.0 mg/well in PBS) were added to the plate which
was then incubated for 1 h at 37uC. Binding of FhHDM-1 or
peptides to LPS was detected by the addition of affinity-purified
rabbit anti-FhHDM-1 (1:5000 dilution in 0.1% BSA/PBS) for 1 h
at 37uC, followed by alkaline phosphatase-conjugated goat anti-
rabbit IgG (Sigma; 1:2000 dilution in 0.1% BSA/PBS). Binding of
secondary antibody was visualised by the addition of p-nitrophenol
phosphate (Sigma; 100 ml/well) and measuring the absorbance at
405 nm. Alternatively, FhHDM-1 or derived peptides (0.1 mg/
well) were added to LPS-coated plates in the presence of LPS (0.05
to 5.0 mg/well) in PBS. Bound peptide was then determined by the
addition of anti-FhHDM-1 antibody as described above.
Assay for the interaction of LPS with LBP
LPS–LBP binding was examined as described previously [80].
Briefly, PBS containing 0.1-10% mouse sera was added to an LPS-
coated microtiter plate (100 ng/well) and incubated for 1 h at
37uC. Bound LBP was detected by the addition of anti-LBP
antibody (Santa Cruz; 1:500 dilution in 0.1% BSA/PBS) followed
by alkaline phosphatase-conjugated rabbit anti-goat IgG (Sigma;
1:1000 dilution on 0.1% BSA/PBS) and measuring the colour
development at 405 nm after addition of p-nitrophenol phosphate
(Sigma; 100 ml/well). To examine the effect of FhHDM-1 or
derived peptides on the interaction between LPS and LBP, LPS-
coated microtiter plates were pre-incubated with either F. hepatica
ES, FhHDM-1, FhHDM-1 p1 or FhHDM-1 p2 (0.01–10 mg/ml)
for 1 h at 37uC prior to the addition of 10% mouse sera in PBS
and assayed as described above.
Assay for binding of FITC-conjugated LPS to RAW 264.7
cells
RAW 264.7 cells (56105/ml) were incubated with FITC-
conjugated LPS (100 ng/ml) in the absence or presence of
FhHDM-1 or derived peptides (0.01 to 10 mg/ml) in RPMI
1640 containing 10% FBS for 20 min at 4uC. After cells were
washed with PBS, the binding of FITC-conjugated LPS was
analysed by measuring median fluorescence intensity using a LSR
II flow cytometer (BD Bioscience).
The effects of FhHDM-1 and derived peptides on
endotoxin-induced inflammation
Following purification of native and recombinant FhHDM-1 by
gel filtration and Ni-NTA agarose chromatography respectively,
residual bacterial endotoxin was removed from the samples using
RP-HPLC using the same conditions as described above.
Synthetic peptides were supplied endotoxin free. Final endotoxin
levels were measured using the Chromo-LAL assay kit (Associates
of Cape Cod, USA) and shown to be ,0.01 EU/ml. Six week-old
female BALB/c mice were purchased from ARC (Perth, Australia)
and maintained according to the guidelines of the University of
Technology Sydney Animal Care and Ethics committee. For the
analysis for endotoxin-induced inflammation, mice were intra-
peritoneally injected with 1 mg of E. coli LPS (serotype 111:B4;
Sigma) either with or without 1 mg FhHDM-1 or derived peptides.
After 2 h mice were euthanized. Plasma was isolated from cardiac
blood by centrifugation at 2000 x g for 10 min and levels of
circulating IL-1b and TNF measured by ELISA (BD Pharmingen).
Additionally, the peritoneal cavities of mice were lavaged and
peritoneal macrophages isolated by adherence to plastic as
previously described [81]. Macrophages were incubated overnight
in RPMI 1640 supplemented with 10% FCS and supernatants
were analysed for the presence of IL-1b and TNF by ELISA.
Accession numbers
FN314266, AM047184, FN314265, FN314266, FN314267,
FN357430, HQ456365, AF281362, AT009171, AT007125,
ES416124, AF109180, EF127841, AY812960, AY814368,
AY915075, FN327058, NM_004345.
Supporting Information
Figure S1 Sedimentation velocity analysis of recombinant
FhHDM-1. Absorbance versus radial position of recombinant
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FhHDM-1 at pH 4.5 (A) and pH 7.3 (B). The residuals for the
resulting c(s) distribution best-fits are shown.
(TIF)
Table S1 Secondary structure proportions of native and
recombinant FhHDM-1.
(DOC)
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